{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-037898","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.972088+00:00","generated_at":"2026-05-29T01:11:54.801286+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Omeros narsoplimab meets TA-TMA pivotal trial primary endpoint; HR 0.32 for survival","bullets":["Narsoplimab-treated TA-TMA patients had over 3-fold reduction in risk of death (HR 0.32, 95% CI 0.23-0.44, p<0.00001) vs >100 external control patients.","Omeros will resubmit the narsoplimab BLA to FDA as soon as possible for first approved TA-TMA therapy.","Expanded access program data: 46% of adults and 50% of children achieved TA-TMA resolution after failing C5 inhibitors.","European marketing authorisation application planned for Q2 2025; additional sensitivity analyses and manuscripts expected early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-037898","json":"https://secwatch.observer/filing/0001437749-24-037898.json","markdown":"https://secwatch.observer/filing/0001437749-24-037898.md","text":"https://secwatch.observer/filing/0001437749-24-037898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924037898/0001437749-24-037898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924037898/omer20241210_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:11:54.801286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}